Friday, 20 Jul 2018

You are here

CDC Lyme Disease Surveillance Report

Lyme disease, caused by the spirochete Borrelia burdofgeri, is the most common vector-borne illness reported in the U.S. Cases occur mainly in the Northeast, Mid-Atlantic and upper Midwest as well as certain areas of the Pacific coast, with a geographic distribution based on residence of Ixodes scapularis (Ixodes pacificus on the West Coast), the vectors that transmits Lyme disease.

Lyme disease has been a reportable disease since 1991, with cases reported to the Health Department by both physicians and laboratories. Confirmed or probable cases are then reported to the CDC through the National Notifiable Diseases Surveillance System.

MMWR recently published surveillance data for Lyme Disease in the U.S. from 2008-2015. States with an average annual incidence ≥ 10 confirmed cases per 100,000 population were considered high incidence. During this time period 275,589 cases of Lyme were reported to the CDC and most cases were from regions previously considered to be high incidence.

According to the CDC surveillance report, the top 7 states for Lyme disease in 2015 include

  1. Vermont (78.4 per 100000/yr)
  2. Maine (74.7 per 100000/yr)
  3. Pennsylvania (57.5 per 100000/yr)
  4. Rhode Island (53.4 per 100000/yr)
  5. Connecticut (52.2 per 100000/yr)
  6. New Jersey (43.9 per 100000/yr)
  7. Massachussetts (43 per 100000/yr).

For the most part these counts have remained stable over the years; however, incidence is rising in states that neighbor these regions. Demographics of reported cases are similar to in the past, but in lower incidence areas there were more cases in younger females compared to the past.

We can take away from this that Lyme disease continues to concentrate in known high-incidence areas although the geographic distribution seems to be spreading. This will add to the continuing public health challenge that is Lyme disease, and Lyme should be considered in a patient with a  suggestive clinical presentation even if they are not from a high risk area.  

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The Lung in RA: Little Progress

The progress that has been seen in the management of many aspects of rheumatoid arthritis (RA) has not been paralleled for the pulmonary disease that remains the second most common cause of death among these patients, an Australian expert reported here at the annual meeting of the Florida Society of Rheumatology.

Ultrasound Tenosynovitis Predicts RA Development

Musculoskeletal ultrasound (US) has become a more widely used tool in rheumatology clinical practice. This study of early inflammatory arthritis patients shows that US-defined digit flexor tenosynovitis was more predictive of subsequent rheumatoid arthritis than findings of ACPA positivity or US-defined joint synovitis.

The Diverse Fate of Seronegative Rheumatoid Arthritis

A Finnish Rheumatology Center followed 435 early, seronegative rheumatoid arthritis (RA) patients for 10-years and found that only 3% became erosive or seropositive RA. They also found that 32% could not be further reclassified, and that the remaining 65% evolve into another diagnosis, led by polymyalgia rheumatica (16%), psoriatic arthritis (11%), spondyloarthritis (9%), and osteoarthritis (10%).  

Does RA Have a Prodrome?

A pattern of increased primary care visits and joint complaints during the 2 years before rheumatoid arthritis (RA) was diagnosed were predictive of the diagnosis, a British case-control study found.

Can DMARDs Delay Rheumatoid Onset?

Preclinical rheumatoid arthritis (RA) is a hot new area wherein at risk individuals (seropositive, first degree relatives of RA patients, etc.) are being studied to assess the triggers that lead to progression to RA or whether therapies can be used to avert the onset of RA.